Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Celldex Therapeutics (CLDX) stocks in Canada

Learn how to easily invest in Celldex Therapeutics stocks.

Celldex Therapeutics is a biotechnology business based in the US. Celldex Therapeutics stocks (CLDX.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $31.04 – a decrease of 8.62% over the previous week. Celldex Therapeutics employs 123 staff and has a trailing 12-month revenue of around $8.1 million.

How to buy shares in Celldex Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – CLDX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Celldex Therapeutics stock price (NASDAQ:CLDX)

Use our graph to track the performance of CLDX stocks over time.

Celldex Therapeutics shares at a glance

Information last updated 2022-01-18.
Latest market close$29.16
52-week range$15.37 - $57.20
50-day moving average $39.43
200-day moving average $39.25
Wall St. target price$65.17
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.76

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Celldex Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Celldex Therapeutics price performance over time

Historical closes compared with the close of $29.16 from 2022-01-20

1 week (2022-01-13) -3.19%
1 month (2021-12-20) -25.46%
3 months (2021-10-17) N/A
6 months (2021-07-21) -32.66%
1 year (2021-01-21) 62.63%
2 years (2020-01-21) 1,151.50%
3 years (2019-01-18) 8,438.80%
5 years (2017-01-20) 755.13%

Celldex Therapeutics financials

Revenue TTM $8.1 million
Gross profit TTM $-35,116,000
Return on assets TTM -10.27%
Return on equity TTM -21.68%
Profit margin 0%
Book value $9.36
Market capitalisation $1.5 billion

TTM: trailing 12 months

Celldex Therapeutics share dividends

We're not expecting Celldex Therapeutics to pay a dividend over the next 12 months.

Have Celldex Therapeutics's shares ever split?

Celldex Therapeutics's shares were split on a 1:15 basis on 10 February 2019. So if you had owned 15 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Celldex Therapeutics shares – just the quantity. However, indirectly, the new 1400% higher share price could have impacted the market appetite for Celldex Therapeutics shares which in turn could have impacted Celldex Therapeutics's share price.

Celldex Therapeutics share price volatility

Over the last 12 months, Celldex Therapeutics's shares have ranged in value from as little as $15.37 up to $57.2. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celldex Therapeutics's is 2.7248. This would suggest that Celldex Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Celldex Therapeutics overview

Celldex Therapeutics, Inc. , a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. Celldex Therapeutics, Inc. has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University.

Stocks similar to Celldex Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site